Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines

• Published in: Metabolomics 2021-12, Vol.17 (12), p.104-104, Article 104
• Main Authors: Varshavi, Dorna, Varshavi, Dorsa, McCarthy, Nicola, Veselkov, Kirill, Keun, Hector C., Everett, Jeremy R.
• Format: Article
• Language: English
• Subjects: Acetic acid; Alleles; Biochemistry; Biomedical and Life Sciences; Biomedicine; Cancer; Cell Biology; Cell Line; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - genetics; Colorectal Neoplasms - metabolism; Developmental Biology; Genetic factors; Genetic transformation; Glutamine; Glutathione; Glycolysis; Humans; K-Ras protein; Life Sciences; Metabolic pathways; Metabolism; Metabolomics; Molecular Medicine; Molecular modelling; Mutants; Mutation; Original; Original Article; Point mutation; Proto-Oncogene Proteins p21(ras) - genetics; Proto-Oncogene Proteins p21(ras) - metabolism; Tricarboxylic acid cycle
• ISSN: 1573-3882; 1573-3890
• DOI: 10.1007/s11306-021-01852-w

Introduction KRAS was one of the earliest human oncogenes to be described and is one of the most commonly mutated genes in different human cancers, including colorectal cancer. Despite KRAS mutants being known driver mutations, KRAS has proved difficult to target therapeutically, necessitating a comprehensive understanding of the molecular mechanisms underlying KRAS -driven cellular transformation. Objectives To investigate the metabolic signatures associated with single copy mutant KRAS in isogenic human colorectal cancer cells and to determine what metabolic pathways are affected. Methods Using NMR-based metabonomics, we compared wildtype (WT)- KRAS and mutant KRAS effects on cancer cell metabolism using metabolic profiling of the parental KRAS G13D/+ HCT116 cell line and its isogenic, derivative cell lines KRAS +/– and KRAS G13D/– . Results Mutation in the KRAS oncogene leads to a general metabolic remodelling to sustain growth and counter stress, including alterations in the metabolism of amino acids and enhanced glutathione biosynthesis. Additionally, we show that KRAS G13D/ + and KRAS G13D/− cells have a distinct metabolic profile characterized by dysregulation of TCA cycle, up-regulation of glycolysis and glutathione metabolism pathway as well as increased glutamine uptake and acetate utilization. Conclusions Our study showed the effect of a single point mutation in one KRAS allele and KRAS allele loss in an isogenic genetic background, hence avoiding confounding genetic factors. Metabolic differences among different KRAS mutations might play a role in their different responses to anticancer treatments and hence could be exploited as novel metabolic vulnerabilities to develop more effective therapies against oncogenic KRAS. Graphical abstract